Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.
Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.
FiercePharma18h
Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer's
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...
It's about to get a lot harder to buy knock-off Ozempic
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?
One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...
What’s behind the meteoric rise of weight-loss drugs in Massachusetts?
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...
GLP-1 weight loss drugs linked to a wide range of health benefits and risks: study
A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, ...
What's next for Viking Therapeutics? Here's how the company can scale up.
Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...
The Health Risks and Benefits of Weight-Loss Drugs
Read More: Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs ...